Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18526705 | 0.91 | ATM (0.65) | KMT2AMEN1L3MBTL1TDP1ATM | |
| SCHEMBL12518836 | 0.85 | HPGD (0.58) | KMT2AMEN1L3MBTL1TDP1ATM | |
| SCHEMBL10722543 | 0.84 | ATM (0.81) | KMT2AMEN1L3MBTL1TDP1ATM | |
| SCHEMBL2866081 | 0.83 | GLA (0.64) | L3MBTL1HPGDALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL10404896 | 0.83 | ATM (0.58) | KMT2AMEN1L3MBTL1TDP1ATM | |
| SCHEMBL10722542 | 0.82 | ATM (0.85) | KMT2AMEN1L3MBTL1TDP1ATM | |
| SCHEMBL28366947 | 0.82 | ATM (0.85) | KMT2AMEN1L3MBTL1TDP1ATM | |
| SCHEMBL27487132 | 0.82 | ATM (0.85) | KMT2AMEN1L3MBTL1TDP1ATM | |
| SCHEMBL12282009 | 0.82 | KDM4E (0.49) | KMT2AMEN1L3MBTL1TDP1ATM | |
| SCHEMBL2701784 | 0.81 | GNAI3 (0.47) | KMT2AMEN1L3MBTL1TDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2008124582-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | KMT2A 4668/4885MEN1 2976/4885L3MBTL1 4439/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | KMT2A 4507/4885MEN1 2421/4885L3MBTL1 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.